Astrana Health stock jumped 4.8% to US$35.76 after earnings, which suggests investors were ready to reward proof that the recent slide was not the whole story. The headline is simple: this is a profit and cash flow moment, not just another revenue update.

Adjusted diluted earnings per share hit US$0.80 in the quarter and free cash flow in the first half reached US$93 million. At the same time, net leverage moved down to 2.26x. The question now is whether that combination of earnings power and de-risking really justifies the renewed enthusiasm in the shares.

Is Astrana Health’s 43.4x P/E a sign the stock is stretched, or does the DCF estimate near US$126 hint at a mispriced opportunity? See how those signals line up in our valuation analysis for Astrana Health

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$972.52 million vs. US$654.81 million (up about 49%).
• Net Income, Q2 2026 vs. Q2 2025: US$19.74 million vs. US$9.42 million (up about 110%).
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.40 per share vs. US$0.19 per share (up about 110%).
• Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$69 million vs. roughly US$48 million (up about 43%).

Prefer visual charts to another wall of earnings tables and ratios? See Astrana Health’s full financial picture, including a clear view of its valuation in our company report for Astrana Health..

Astrana Health’s Bull Case Meets Concrete Milestones

The bullish story around Astrana Health rests on full risk value based care and the Prospect deal driving operating leverage rather than just raw growth. Q2 provides several concrete milestones in that direction. About 81% of capitation revenue and 42% of membership now sit in full risk arrangements, and new Texas full risk cohorts are said to be performing in line with underwriting. That directly supports the claim that Astrana can responsibly take on more medical cost exposure without losing economics.

The Prospect acquisition is another key plank. One year in, provider retention is above 99% and management expects synergies at the high end of the US$12 million to US$15 million range, with medical cost trends at Prospect slightly better than expected. In addition, there has been a roughly 210 basis point improvement in G&A as a share of revenue and improved free cash flow, providing quantitative support for the operating leverage aspect of the bull case.

Compare Astrana Health’s internal targets for full risk growth and Prospect synergies with how the Street is recalibrating expectations right now. See the consensus price target analysis for Astrana Health

Astrana Health Bear Case: What Still Hasn’t Cleared

The bearish narrative around Astrana Health centers on whether policy exposure, integration risk and capital intensity will eventually squeeze margins and dull returns on this growth. The latest quarter pushes back on some of that, yet leaves several bearish checkpoints unresolved.

On the positive side, Prospect integration is hitting stated milestones. Provider retention is above 99% and synergy targets are tracking toward the high end of the US$12 million to US$15 million range. Net leverage is lower and free cash flow conversion in the first half is solid.

However, bears who worry about public program volatility and capital efficiency still have room to argue their case. Medicaid attrition is tracking toward the high end of expectations. Management is reinvesting part of EBITDA outperformance into new cohorts and tuck-in deals, which delays any clear read on whether returns on invested capital are improving or merely being recycled into more execution risk.

Review whether Astrana Health’s current leverage, reinvestment pace and interest coverage issues are early warning signs by reading our risk analysis for Astrana Health which shows 1 important warning sign.

Own Your Next Investing Move

If Astrana Health’s mix of full risk growth, Prospect integration progress and a 43.4x P/E has caught your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch for a setup that fits your plan. Once you are invested, use the Portfolio Command Center to keep your holdings organised and focus only on the updates that really matter. For a longer term view, tap into crowd insights through the Community and see how other investors are reacting to new data points on Astrana Health. This combination can help you identify potential catalysts or risks early and stay informed.

Seeking Alternatives Beyond Astrana Health?

Fresh ideas move first. Stocks with real breakout potential can get picked over fast once momentum starts flying. Scan these focused shortlists while it matters and get in early.

• Spot cash rich companies with room to run by reviewing the curated list of solid balance sheet and fundamentals stocks (49 results) before that strength is fully priced in.
• Chase durable income streams while yields are still elevated by scanning the hand picked 8 dividend fortresses that could keep portfolios steadier when prices are jumping around.
• Target early movers in AI infrastructure by checking the focused 55 AI infrastructure stocks before the strongest operators are fully caught by the wider market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.